Hope for rare fatal brain disease: drug trial shows promise
NCT ID NCT04611880
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tested a drug called crizanlizumab in 18 adults with RVCL, a rare and fatal genetic condition that damages small blood vessels in the brain and eyes. The goal was to see if the drug could slow the growth of brain lesions seen on MRI scans. While not a cure, the trial aimed to control the disease and offer a potential treatment option for a condition with no current therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RVCL - RETINAL VASCULOPATHY CEREBRAL LEUKOENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Andria Ford
St Louis, Missouri, 63110, United States
-
Perelman School of Medicine; University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.